Affiliation:
1. Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania
Abstract
Phosphodiesterase type 5 (PDE5) is pivotal in cellular signalling, regulating cyclic guanosine monophosphate (cGMP) levels crucial for smooth muscle relaxation and vasodilation. By targeting cGMP for degradation, PDE5 inhibits sustained vasodilation. PDE5 operates in diverse anatomical regions, with its upregulation linked to various pathologies, including cancer and neurodegenerative diseases. Sildenafil, a selective PDE5 inhibitor, is prescribed for erectile dysfunction and pulmonary arterial hypertension. However, considering the extensive roles of PDE5, sildenafil might be useful in other pathologies. This review aims to comprehensively explore sildenafil’s therapeutic potential across medicine, addressing a gap in the current literature. Recognising sildenafil’s broader potential may unveil new treatment avenues, optimising existing approaches and broadening its clinical application.
Reference282 articles.
1. Past, present, and future: A 7-year update of Viagra® (sildenafil citrate);Jackson;Int. J. Clin. Pract.,2005
2. Versatile effects of sildenafil: Recent pharmacological applications;Uthayathas;Pharmacol. Rep.,2007
3. A review search of sildenafil uses in human and in the veterinary medicine;Kadhim;AIP Conf. Proc.,2023
4. Simonca, L., and Tulloh, R. (2017). Sildenafil in Infants and Children. Children, 4.
5. Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond;Ghofrani;Nat. Rev. Drug Discov.,2006